Knight Therapeutics Inc (TSE:GUD) – Cormark issued their Q1 2020 EPS estimates for shares of Knight Therapeutics in a research note issued on Monday, March 18th. Cormark analyst T. Gonsalves expects that the company will earn $0.03 per share for the quarter. Cormark also issued estimates for Knight Therapeutics’ Q2 2020 earnings at $0.03 EPS, Q3 2020 earnings at $0.03 EPS, Q4 2020 earnings at $0.02 EPS and FY2020 earnings at $0.11 EPS.
Separately, Raymond James set a C$10.25 price objective on Knight Therapeutics and gave the company an “outperform” rating in a research note on Friday, March 15th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of C$10.06.
Knight Therapeutics (TSE:GUD) last posted its quarterly earnings data on Thursday, March 14th. The company reported C$0.04 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of C$0.03 by C$0.01. The business had revenue of C$3.89 million for the quarter, compared to the consensus estimate of C$2.55 million.
Knight Therapeutics Company Profile
Knight Therapeutics Inc operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Impavido, an alkyllysophospholipid analogue drug for visceral and cutaneous Leishmaniasis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; and Flat Tummy Tea, a herbal detox tea.
Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.